Improvement of vascular function by chronic administration of a cyclo-oxygenase inhibitor in cholesterol-fed rabbits

Clinical and Experimental Pharmacology and Physiology

Volumn 30, Issue 5-6, 2003, Pages 405-412

  Srisawat, Supath ^a   Phivthong Ngam, Laddawal ^b   Unchern, Supeenun ^a   Chantharaksri, Udom ^a   Govitrapong, Piyarat ^c   Sanvarinda, Yupin ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Acetylcholine; Cyclo oxygenase inhibitor; Endothelium; Indomethacin; Isoprostane; Nitric oxide; Plaque; Prostaglandin

Indexed keywords

2,3 DINORTHROMBOXANE B2; 6 OXOPROSTAGLANDIN F1 ALPHA; 8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; CHOLESTEROL; INDOMETACIN; NITRATE; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE A2;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL FUNCTION; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIET; ENDOTHELIUM; MALE; MORTALITY; NONHUMAN; RABBIT; THROMBOCYTE AGGREGATION; URINARY EXCRETION;

ANIMALS; AORTA, THORACIC; ARTERIOSCLEROSIS; CHOLESTEROL, DIETARY; CYCLOOXYGENASE INHIBITORS; ENDOTHELIUM, VASCULAR; MALE; RABBITS; VASODILATION;

EID: 0038809114     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2003.03850.x     Document Type: Article

References (58)

1. Ross R. Atherosclerosis: An inflammatory disease. N. Engl. J. Med. 1999; 340: 115-26.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
3. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 1997; 96: 2751-3.
4. Vanhoutte PM. The endothelium: Modulator of vascular smooth muscle tone. N. Engl. J. Med. 1988; 319: 512-13.
5. Feelisch M, te-Poel M, Zamora R, Deussen A, Moncada S. Understanding the controversy over the identity of EDRF. Nature 1994; 368: 62-5.
6. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br. J. Pharmacol. 1988; 93: 515-24.
7. 2 biosynthesis capacities of heart, arteries and platelets at various stages of experimental atherosclerosis in rabbits. Atherosclerosis 1978; 31: 385-94.
8. Phivthong-ngam L, Böde-Böger SM, Böger RH et al. Dietary L-arginine normalizes endothelin-induced vascular contractions in cholesterol-fed rabbits. J. Cardiovasc. Pharmacol. 1998; 32: 300-7.
9. Miller VM, Vanhoutte PM. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxygenase. Am. J. Physiol. 1985; 248: H432-7.
10. Mügge A, Brandes RP, Böger RH, Frölich JC. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. 1994; 24: 994-8.
11. Förstermann U, Mügge A, Alheid U, Haverich A, Frölich JC. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ. Res. 1988; 62: 185-90.
12. Guerra R, Brotherton AF, Goodwin PJ, Clark CR, Armstrong ML, Harrison DG. Mechanisms of abnormal endothelium-dependent vascular relaxation in atherosclerosis. Implications for altered autocrine and paracrine functions of EDRF. Blood Vessels 1989; 26: 300-14.
13. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherosclerotic effects of L-arginine in the hypercholesterolemic rabbits. J. Clin. Invest. 1992; 90: 1168-72.
14. Böger RH, Böde-Böger SM, Mügge A et al. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 1995; 117: 273-84.
15. Böde-Böger SM, Böger RH, Raff P, Phivthong-ngam L, Frölich JC. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits comparison with lavastatin. Circulation 1997; 96: 1282-90.
16. Luscher TF, Aarhus LL, Vanhoutte PM. Indomethacin improves the impaired endothelium-dependent relaxations in small mesenteric arteries of the spontaneously hypertensive rat. Am. J. Hypertens. 1990; 3: 55-8.
17. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-33.
18. Katz SD, Schwarz M, Yuen J, LeJemtel TH. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure: Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993; 88: 55-61.
19. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998; 97: 716-20.
20. Jouve R, Juhan-Vague I, Aillaud M, Serment-Jouve M, Payan H. Comparison of the effects of aspirin and indomethacin on aortic atherogenesis induced in rabbits. Atherosclerosis 1982; 42: 319-21.
21. Böger RH, Böde-Böger SM, Schroder EP, Tsikas D, Frölich JC. Increased prostacyclin production during exercise in untrained and trained men: Effect of low-dose aspirin. J. Appl. Physiol. 1995; 78: 1832-8.
22. Böger RH, Böde-Böger SM, Gutzki FM, Tsikas D, Weskott HP, Frölich JC. Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man. Clin. Sci. 1993; 84: 517-24.
23. 3- excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-NAME in rats. Clin. Exp. Pharmacol. Physiol. 1996; 23: 11-15.
24. Fisher LD, van Belle G. Multiple comparisons. In: Fisher LD, van Belle G (eds). Biostatistics: A Methodology for the Health Sciences. Wiley, New York. 1993; Ch. 5.
25. Praticò D, Tillmann C, Zhang Z-B, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl Acad. Sci. USA 2001; 98: 3358-63.
26. 2 on proliferation of vascular smooth muscle cells from rats. Am. J. Physiol. 1992; 263: H1331-8.
27. 2-stimulated mitogenesis of coronary artery smooth muscle cells involves activation of mitogen-activated protein kinase and S6 kinase. J. Biol. Chem. 1994; 269: 5693-8.
28. 2 synthesis in hypercholesterolaemic rabbits in vivo. Cardiovasc. Res. 1998; 37: 756-64.
29. Praticó D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 2000; 96: 3823-6.
30. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-5.
31. Carvalho ACA, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N. Engl. J Med. 1974; 290: 434-8.
32. 2 formation in type-II hyperlipoproteinemia patients. Eur. J. Clin. Invest. 1984; 14: 329-33.
33. 2 synthase in human monocytes. J. Biol. Chem. 1990; 265: 16 737-40.
34. Hempel SL, Monick MM, Hunninghake GW. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J. Clin. Invest. 1994; 93: 391-6.
35. Cipollone F, Patrignani P, Greco A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997; 96: 1109-16.
36. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase isoenzymes by aspirin and other NSAIDs. J. Biol. Chem. 1993; 268: 6610-14.
37. 2-isoprostanes, are present in increased amounts in atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 3236-41.
38. 2 isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 1997; 100: 2028-34.
39. Reilly MP, Pratico D, Delanty N et al. Increased formation of distinct F isoprostanes in hypercholesterolemia. Circulation 1998; 98: 2822-8.
40. 2α is increased in hypercholesterolaemia. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 3230-5.
41. Böger RH, Böde-Böger SM, Phivthong-ngam L. Dietary L-arginine and α-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms. Atherosclerosis 1998; 141: 31-43.
42. Ohara Y, Peterson PE, Harrison DG. Hypercholesterolemia increases endothelial superoxide production. J. Clin. Invest. 1993; 91: 25 846-58.
43. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 334: 793-5.
44. Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: Formation analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem 1999; 35: 24 441-4.
45. Roberts LJ, Morrow JD. The generation and actions of isoprostanes. Biochim. Biophys. Acta 1997; 1345: 121-35.
46. 2α). Eur. J. Pharmacol. 2000; 393: 161-8.
47. Cipolione F, Ciabattoni G, Patrignani P et al. oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102: 1007-13.
48. 2α in vitro and in vivo via the cyclooxygenases. J. Pharmacol. Exp. Ther. 1997; 282: 1658-65.
49. 2α. J. Biol. Chem. 1995; 270: 9800-8.
50. 2α by human monocytes. J. Biol. Chem. 1996; 271: 8919-24.
51. Bailey JM, Butler J. Anti-imflammatory drug in experimental atherosclerosis. Part 6. Combination therapy with steroid and non-steroid agent. Atherosclerosis 1985; 54: 205-9.
52. Maier JM, Barenghi L, Bradamante S, Pagani F. Modulators of oxidized LDL-induced hyperadhesiveness in human endothelial cells. Biochem. Biophys. Res. Commun. 1994; 204: 673-7.
53. Kreuzer J, Denger S, Jahn L et al. LDL stimulates chemotaxis of human monocytes through a cyclooxygenase-dependent pathway. Arterioscler. Thromb. Vasc. Biol. 1996; 16: 1481-7.
54. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol. Rev. 1991; 43: 109-42.
55. Clowes AW, Clowes MM, Reidy MA. Kinetics of cellular proliferation after arterial injury III. Endothelial and smooth muscle growth in chronically denuded vessels. Lab. Invest. 1986; 54: 295-303.
56. Yan ZQ, Hanson KG. Overexpression of inducible nitric oxide synthase by neointemal smooth muscle cells. Circ. Res. 1998; 82: 21-9.
57. Yan ZQ, Yokota T, Zhang W, Hansson GK. Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery. Circ. Res. 1996; 79: 38-44.
58. Shimpo M, Ikeda U, Maeda M. Effects of aspirin-like drugs on nitric oxide synthesis in rat vascular smooth muscle cells. Hypertension 2000; 35: 1085-91.